Therefore, in light of the hypothesis that plasma cell depletion through CD38 targeting may be therapeutically rewarding in SSc patients, the present study aimed at evaluating the levels of circulating CD38high plasma cells and the expression of CD38 in other peripheral blood mononuclear cells (PBMCs) in a cohort of patients with SSc. This evidence concerns the gene CD38 and systemic sclerosis.